Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.50 |
| ▸ | BRAF | P15056 | 4/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.50 |
| ▸ | TNNI3K | Q59H18 | 4/20 | 0.50 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 10/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2762297 | 0.89 | KDR (0.52) | KDRBRAFMAPK14TNNI3KGSK3A | |
| SCHEMBL2762586 | 0.88 | KDR (0.47) | KDRBRAFMAPK14TNNI3KMET | |
| SCHEMBL2763212 | 0.87 | KDR (0.52) | KDRBRAFMAPK14TNNI3KGSK3A | |
| SCHEMBL2763083 | 0.87 | KDR (0.52) | KDRBRAFMAPK14TNNI3KCDK8 | |
| SCHEMBL2762807 | 0.83 | KDR (0.48) | KDRBRAFMAPK14TNNI3KGSK3A | |
| SCHEMBL2762754 | 0.82 | BRAF (0.63) | KDRBRAFMAPK14TNNI3K | |
| SCHEMBL2762816 | 0.82 | BRAF (0.49) | KDRBRAFMAPK14TNNI3KMET | |
| SCHEMBL2762819 | 0.82 | KDR (0.74) | KDRBRAFMAPK14TNNI3KCDK8 | |
| SCHEMBL2763582 | 0.81 | BRAF (0.57) | KDRBRAFMAPK14TNNI3K | |
| SCHEMBL2762478 | 0.81 | KDR (0.68) | KDRBRAFMAPK14TNNI3KCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080552-B2 | Pyrimidyl derivatives as protein kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2011-12-20 | — | — | US | claimed |
| EP-2102173-B1 | PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-10-20 | — | — | EP | claimed |
| US-20100041684-A1 | PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2010-02-18 | — | — | US | claimed |
| EP-2102173-A1 | PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-09-23 | — | — | EP | claimed |
| WO-2008077548-A1 | PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | WO | claimed |
| US-8080552-B2 | Pyrimidyl derivatives as protein kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-2102173-B1 | PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-10-20 | — | — | EP | disclosed |
| US-20100041684-A1 | PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2010-02-18 | — | — | US | disclosed |
| EP-2102173-A1 | PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008077548-A1 | PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041684-A1 | PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP3K5, MAP3K1, MAP4K2 | KDR 1270/4885BRAF 47/4885MAPK14 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.